CD154 blockade effectively controls antibody-mediated rejection in highly sensitized nonhuman primate kidney transplant recipients
Science Translational Medicine · 2025-01 · 17 (779)
DOI: 10.1126/scitranslmed.adn8130 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Translational Medicine, 2025-01. Verfasst von Imran J Anwar und 16 weiteren Autor:innen. Beteiligte Einrichtung: Duke Transplant Center, Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA. Hauptthemen laut MEDLINE: Kidney Transplantation, CD40 Ligand, Graft Rejection, Antibodies, Monoclonal. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS.
Abstract (Originalsprache)
Current desensitization and maintenance immunosuppression regimens for kidney transplantation in sensitized individuals show limited ability to control the posttransplant humoral response, resulting in high rates of antibody-mediated rejection (ABMR) and graft failure. Here, we showed that anti-CD154 monoclonal antibody (mAb)–based immunosuppression more effectively controlled allograft rejection and humoral rebound in a highly sensitized nonhuman primate kidney transplantation model compared with tacrolimus-based standard-of-care (SOC) immunosuppression. Desensitization with an anti-CD154 mAb (5C8) and a proteasome inhibitor led to decreased donor-specific antibodies (DSAs) and disruption of lymph node germinal centers with reduction of proliferating, memory, and class-switched B cells as well as T follicular helper cells. After transplant, the nonhuman primates maintained on 5C8-based immunosuppression had significantly better survival compared with those maintained on SOC immunosuppression (135.2 days versus 32.8 days, P = 0.013). The 5C8-treated group demonstrated better suppression of DSAs after transplant, more robust suppression of B cell populations, and better induction of regulatory T cells. Fewer infectious and welfare complications, including viral reactivation and weight loss, were also observed with 5C8-based immunosuppression compared with SOC immunosuppression. Therefore, anti-CD154 mAbs may improve kidney transplant outcomes through better control of posttransplant immune responses. The superior efficacy of anti-CD154 mAb–based immunosuppression over tacrolimus-based SOC seen in this highly sensitized NHP transplant model suggests that anti-CD154 mAbs could potentially be used to desensitize and treat highly sensitized patients receiving kidney transplantation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Duke Transplant Center, Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA.
- Department of Biostatistics & Bioinformatics, Duke University Medical Center, Durham, NC 27710, USA.
- Department of Pathology, Emory University School of Medicine, Atlanta, GA 30322, USA.
- Nonhuman Primate Reagent Resource, UMass Chan Medical School, Worcester, MA 01605, USA.
ORCID-Profile: Imran J Anwar, Isabel DeLaura, Joseph M Ladowski, Davide Schilirò, Qimeng Gao, Miriam Manook, Janghoon Yoon, Rafaela Belloni, Angela Park, Daniel J Schuster, Mingqing Song, Lin Lin, Alton B Farris, Diogo Magnani, Jean Kwun, Stuart J Knechtle
Förderung
- NIAID NIH HHS
Zitieren
APA
Anwar, I. J., DeLaura, I., Ladowski, J. M., Schilirò, D., Gao, Q., Manook, M., Yoon, J., Belloni, R., Park, A., Schuster, D. J., Song, M., Lin, L., Farris, A. B., Magnani, D., Williams, K., Kwun, J., & Knechtle, S. J. (2025). CD154 blockade effectively controls antibody-mediated rejection in highly sensitized nonhuman primate kidney transplant recipients. Science Translational Medicine, 17(779). https://doi.org/10.1126/scitranslmed.adn8130
Vancouver
Anwar IJ, DeLaura I, Ladowski JM, Schilirò D, Gao Q, Manook M, et al. CD154 blockade effectively controls antibody-mediated rejection in highly sensitized nonhuman primate kidney transplant recipients. Science Translational Medicine. 2025;17(779). doi:10.1126/scitranslmed.adn8130
BibTeX
@article{Anwar2025,
author = {Anwar, Imran J and DeLaura, Isabel and Ladowski, Joseph M and Schilirò, Davide and Gao, Qimeng and Manook, Miriam and Yoon, Janghoon and Belloni, Rafaela and Park, Angela and Schuster, Daniel J and Song, Mingqing and Lin, Lin and Farris, Alton B and Magnani, Diogo and Williams, Kyha and Kwun, Jean and Knechtle, Stuart J},
title = {CD154 blockade effectively controls antibody-mediated rejection in highly sensitized nonhuman primate kidney transplant recipients},
journal = {Science Translational Medicine},
year = {2025},
volume = {17},
number = {779},
doi = {10.1126/scitranslmed.adn8130}
}
EUVIMED